| Cox Eye Care | |
|
821 Hogan Lane, Suite 500, Conway, AR 72034 | |
| (501) 548-0226 | |
| (501) 548-3591 |
| Full Name | Cox Eye Care |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 821 Hogan Lane, Suite 500, Conway, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972735546 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cox Eye Care 821 Hogan Lane, Suite 500, Conway, AR 72034 Ph: (501) 548-0226 | Cox Eye Care 821 Hogan Lane, Suite 500, Conway, AR 72034 Ph: (501) 548-0226 |
News Archive
Despite their high accuracy, the majority of the existing instrumental laboratory methods are very laborious and insufficient in terms of quick analysis of the objects under study.
Independent evaluators have found that measurable progress in reducing the rates of some targeted HAIs has been achieved under the umbrella of a national plan to prevent HAIs that was developed by the U.S. Department of Health and Human Services (HHS).
Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group. However, the processes now used require harsh reaction conditions or only work in a small number of cases, limiting their usefulness for synthesizing new drug candidates for testing.
Actavis, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for Buprenorphine HCl and Naloxone HCl Dihydrate SL Tablets, 2 mg/0.5 mg and 8 mg/2 mg, the generic equivalent to Reckitt Benckiser Healthcare's Suboxone.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
› Verified 8 days ago
Dr. Leigh E Cox, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 821 Hogan Ln, Suite 500, Conway, AR 72034 Phone: 501-548-0226 Fax: 501-548-3591 | |
Arkansas Eye Care Group Optometrist Medicare: Medicare Enrolled Practice Location: 3005 Fountain Drive, Conway, AR 72034 Phone: 501-329-9851 Fax: 501-329-9854 | |
Park-todd Eye Clinic Optometrist Medicare: Not Enrolled in Medicare Practice Location: 552 Locust St, Conway, AR 72034 Phone: 501-329-6859 Fax: 501-329-6850 | |
Dr. Rebecca M King, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 201 Skyline Dr Ste 37, Conway, AR 72032 Phone: 501-450-9191 Fax: 501-450-9922 | |
Deblack Eye Care Center, P.a. Optometrist Medicare: Medicare Enrolled Practice Location: 4150 Tyler Street,, Suite 1, Conway, AR 72034 Phone: 501-329-7878 Fax: 501-329-7881 | |
Dr. James Warren Stuckey, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1155 Highway 65 North, Conway, AR 72032 Phone: 501-328-9500 Fax: 501-328-5148 | |
Ron Boyles, Od Optometrist Medicare: Medicare Enrolled Practice Location: 1100 S Amity Rd Ste A, Conway, AR 72032 Phone: 501-388-2020 |